Asparaginase Erwinia Chrysanthemi

Phase 2

Incyte Corporation (INCY)

15%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

2

Regulatory Approvals

Upcoming Catalysts

Feb 1

INCYPhase 2Phase 2

Asparaginase Erwinia Chrysanthemi Phase 2 Results Expected

Asparaginase Erwinia Chrysanthemi • Leukemia

Drug Information

Target Indication

Leukemia

Clinical Trial

NCT02723994

Last updated: 12/4/2025

Regulatory Approvals

EMA6/26/2018

Graspa

Treatment of acute lymphoblastic leukaemia

Orphan

View on EMA

EMA1/13/2016

Spectrila

Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.

View on EMA

Developer

INCY

Incyte Corporation

Biotechnology•North America•NASDAQ